Home | Industry Information | Business News | Browse by Publication | W | Worldwide Biotech

SATRAPLATIN REDUCES RISK OF PROSTATE CANCER PROGRESSION.

Publication: Worldwide Biotech
Publication Date: 01-APR-07
Format: Online
Delivery: Immediate Online Access

Article Excerpt
GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ: GPCB) and Pharmion Corporation (NASDAQ: PHRM) have announced that final progression-free survival (PFS) results for the double-blind, randomized satraplatin Phase 3 registrational trial, the SPARC trial (Satraplatin and were...

View more below

You can view this article PLUS...

  • Hundreds of the most trusted magazines, newspapers, newswires, and journals (see list)
  • Business news from North America and around the World
  • More than 10 years of article archives
  • Unlimited Access at any time - ONLINE and all in ONE place

Now for a Limited Time, try Goliath Business News - Free for 7 Days!
Tell Me More   Terms and Conditions
Already a subscriber?
Log in to view full article
Purchase this article for $4.95

...Prednisone Against Refractory Cancer) presented recently at the ASCO Prostate Cancer Symposium. The trial is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone- refractory prostate cancer (HRPC) who have failed prior chemotherapy. All analyses of PFS being presented were conducted on an intent-to-treat basis.

The study data show that satraplatin significantly reduces the risk of disease progression in these patients using the protocol-specified log-rank test. The hazard ratio of 0.6 (95% CI: 0.5-0.7, p<0.00001), which was first reported in September 2006, adjusted for nine pre-specified prognostic factors. Using a more conservative analysis, which adjusted only for the three pre-specified stratification factors, the hazard ratio is 0.67 (95% CI: 0.57-0.77, p=3D0.0000003). These hazard ratio numbers correspond to a reduction in relative risk of disease progression of 40% and 33%, respectively.

In accordance with the recommendation of the independent Data Monitoring Board for the SPARC trial, patients who have not progressed continue to be treated and all patients will be followed for overall survival. Overall survival data are expected to be available later this year. GPC Biotech recently completed the New Drug Application (NDA) submission for satraplatin to the U.S. Food and...

NOTE: All illustrations and photos have been removed from this article.

Access Full Article, Compliments of Goliath


Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.